← Back
Data updated: Jun 28, 2026
XTM CONSULTING
Pharma Pharmaceuticals
XTM CONSULTING is a pharmaceutical company with 1 FDA-approved products.
2025
Since
1
Drugs
-
Trials
2
New Drugs (2yr)
Modality:
1 Small Molecules
XTM CONSULTING's Key Drugs
XTM CONSULTING's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
No active drugs
XTM CONSULTING's Recent FDA Approvals
XTM CONSULTING secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
XTM CONSULTING's Therapeutic Areas
Disease areas where XTM CONSULTING has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
XTM CONSULTING Pipeline Snapshot
Active clinical trials for XTM CONSULTING across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2025-08-28
- Latest
- 2025-08-28
- Applications
- 1